Tyrosine kinase inhibitors in chronic myeloid leukemia

Cancer Journal from Scientific American

Volumn 5, Issue 2, 1999, Pages 63-69

  Sawyers, Charles L ^a   Druker, Brian ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; INTERFERON; PROTEIN TYROSINE KINASE INHIBITOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BLAST CELL CRISIS; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DRUG EFFECT; DRUG EFFICACY; HUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTO ONCOGENE; SIGNAL TRANSDUCTION; TOXICITY TESTING;

ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; INTERFERONS; LEUKEMIA, MYELOID, CHRONIC; PROTEIN-TYROSINE KINASES;

EID: 0032921194     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996;17: S5-S6.
2. van Rhee F, Szydlo RM, Hermans J et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Bone Marrow Transplant 1997;20: 553-560.
3. Clift RA, Anasetti C. Allografting for chronic myeloid leukaemia. Bailliere's Clin Haematol 1997;10:319-336.
4. O'Brien SG. Autografting for chronic myeloid leukaemia. Bailliere's Clin Haematol 1997;10:369-388.
5. McGlave P, Bartsch G, Anasetti C et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the national marrow donor program. Blood 1993; 81:543-550.
6. McGlave P, Kollman C, Shu XO et al. The first 1000 unrelated donor transplants for CML: lessons from the National Marrow Donor Program (NMDP) experience [abstract]. Blood 1996;88: 483a.
7. Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998;338:962-968.
8. Talpaz M, McCredie KB, Mavligit GM et al. Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 1983;62:689-692.
9. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Inteferon alfa-2 as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994;330:820-825.
10. Hehlmann R, Heimpel H, Hasford J et al. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994;84:4064-4077.
11. Ohnishi K, Ohno R, Tomonaga M et al. A randomized trial comparing interferon-α with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 1995;86:906-916.
12. Allan NC, Richards SM, Shepherd PC. UK medical research council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995;345:1392-1397.
13. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials. J Natl Cancer Inst 1997; 89:1616-1620.
14. Kantarjian HM, Smith TL, O'Brien S et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 1995;122:254-261.
15. Guilhot F, Chastang C, Michallet M et al. Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337:223-229.
16. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497.
17. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa banding. Nature 1973;243:290-291.
18. Bernstein R. Cytogenetics of chronic myelogenous leukemia. Semin Hematol 1988;25:20-34.
19. Sill H, Goldman JM, Cross NC. Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 1995;85:2013-2016.
20. Ahuja H, Bar-Eli M, Arlin Z et al. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 1991;87:2042-2047.
21. Pane F, Frigeri F, Sindona M et al. Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood 1996;88:2410-2414.
22. Lugo TG, Pendergast A, Muller AJ et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079-1082.
23. Voncken JW, Kaartinen V, Pattengale PK et al. BCR/ABL p210 and p190 cause distinct leukemia in transgenic mice. Blood 1995; 86:4603-4611.
24. van Etten RA, Jackson P, Baltimore D. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 1989;58: 669-678.
25. Lewis JM, Baskaran R, Taagepera S et al. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci USA 1996;93:15174-15179.
26. Nichols GL, Raines MA, Vera JC et al. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotem in chronic myelogenous leukemia cells. Blood 1994;84:2912-2918.
27. + leukemia. Blood 1994;84:1731-1736.
28. Oda T, Heaney C, Hagopian JR et al. Crkl is me major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994;269:22925-22928.
29. dok: a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell 1997;88:197-204.
30. Yamanashi Y, Baltimore D. Identification of the Abl- and ras-GAP-associated 62 kDa protein as a docking protein, Dok. Cell 1997;88:205-211.
31. Salgia R, Uemura N, Okuda K et al. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem 1995;270:29145-29150.
32. de Jong R, ten Hoeve J, Heisterkamp N et al. Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-positive leukemia. J Biol Chem 1995;270:21468-21471.
33. Afar DE, Han L, McLaughlin J et al. Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1. Immunity 1997;6:773-782.
34. Mandanas RA, Leibowitz DS, Gharenbaghi K et al. Role of p21 Ras in p210 bcr-abl transformation of murine myeloid cells. Blood 1993;82:1838-1847.
35. Okuda K, Matulonis U, Salgia R et al. Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp Hematol 1994;22: 1111-1117.
36. Skorski T, Kanakaraj P, Nieborowska-Skorska M et al. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995;86:726-736.
37. Raitano AB, Halpern JR, Hambuch TM et al. The Bcr-Abl leukemia oncogene activates Jun Kinase and requires Jun for transformation. Proc Natl Acad Sci U S A 1995;92:11746-11750.
38. Sawyers CL, Callahan W, Witte ON. Dominant negative myc blocks transformation by ABL oncogenes. Cell 1992;70:901-910.
39. Shuai K, Halpern J, ten Hoeve J et al. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996;13:247-254.
40. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996;183:811-820.
41. Ilaria RL, van Etten RA. P210 and P190 BCR/ABL induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996;271:31704-31710.
42. Chang C-J, Geahlen RL. Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Natl Prod 1992;55: 1529-1560.
43. Casnellie JE. Protein kinase inhibitors: probes for the functions of protein phosphorylation. Adv Pharmacol 1991;22:167-205.
44. Boutin JA. Tyrosine protein kinase inhibition and cancer. Int J Biochem 1994;26:1203-1226.
45. Yaish P, Gazit A, Gilon C et al. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 1988; 242:933-935.
46. Kaur G, Gazit A, Levitzki A et al. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anticancer Drugs 1994; 5:213-222.
47. Anafi M, Gazit A, Zehavi A et al. Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood 1993;82:3524-3529.
48. Honma Y, Okabe KJ, Hozumi M et al. Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res 1989;49:331-334.
49. Honma Y, Okabe-Kado J, Kasukabe T et al. Inhibition of abl oncogene tyrosine kinase induces erythroid differentiation of human myelogenous leukemia K562 cells. Jpn J Cancer Res 1990; 81:1132-1136.
50. Kawada M, Tawara J, Tsuji T et al. Inhibition of Abelson oncogene function by etbstatin analogues. Drugs Exp Clin Res 1993; 19:235-241.
51. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 1996;2:561-566.
52. Buchdunger E, Zimmermann J, Mett H et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-104.
53. Buchdunger E, Müller M, Cioffi C et al. Extended in vitro and in vivo profile of CGP 57148, a potent protein tyrosine kinase inhibitor. Submitted.
54. Carroll M, Ohno-Jones S, Tamura S et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGFR fusion proteins. Blood 1997;90: 4947-4952.
55. Beran M, Cao X, Estrov Z et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin Cancer Res 1998;4:1661-1672.
56. Deininger MW, Goldman JM, Lydon N et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90:3691-3698.
57. Gambacorti-Passerini C, le Coutre PLM, Fanelli M et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997;23:380-394.
58. Druker BJ, Sawyers CL, Talpaz M et al. Phase I trial of a specific ABL tyrosine kinase inhibitor, CGP 57148, in interferon refractory chronic myelogenous leukemia patients [abstract]. Blood 1998; 92:252a.
59. Laneuville P, Sun G, Timm M et al. Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl. Blood 1992;80:1788-1797.
60. Raskind WH, Ferraris AM, Najfeld V et al. Further evidence of the existence of a clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukemia. Leukemia 1993;7:1163-1167.
61. Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988;319:990-998.
62. Dunbar CE, Stewart FM. Separating the wheat from the chaff: selection of benign progenitor cells in chronic myeloid leukemia. Blood 1992;79:1107-1110.
63. O'Brien SG, Goldman JM. Current approaches to hematopoietic stem-cell purging in chronic myeloid leukemia. J Clin Oncol 1995; 13:541-546.
64. Heldin CH, Westermark B. Platelet-derived growth factor: mechanism of action and possible in vivo function. Cell Regul 1990;1: 555-566.
65. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995;267:1782-1788.
66. Raitano AB, Whang Y, Sawyers CL. Signal transduction by wild-type and leukemogenic Abl proteins. BBACAN 1997;1333:F201-F216.